Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction
| Autor: | Rudolf A. de Boer, Salva R. Yurista, Harry van Goor, Silke U. Oberdorf-Maass, Jan-Luuk Hillebrands, Hiddo J.L. Heerspink, Herman H W Silljé, B. Daan Westenbrink, Luiz de Menezes Montenegro |
|---|---|
| Přispěvatelé: | Cardiovascular Centre (CVC), Groningen Institute for Organ Transplantation (GIOT), Groningen Kidney Center (GKC), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Myocardial Infarction Diuresis Renal function Heart failure 030209 endocrinology & metabolism 030204 cardiovascular system & hematology Kidney Ventricular Function Left Bone resorption Rats Sprague-Dawley Ventricular Dysfunction Left 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Glucosides Internal medicine Animals Medicine Pharmacology (medical) Benzhydryl Compounds Sodium-Glucose Transporter 2 Inhibitors Pharmacology Bone mineral business.industry Diabetes General Medicine Resorption Disease Models Animal medicine.anatomical_structure Endocrinology chemistry Original Article Sodium–glucose co-transporter 2 inhibitors Diuretic Cardiology and Cardiovascular Medicine business Biomarkers EMPA |
| Zdroj: | Cardiovascular Drugs and Therapy, 34(3), 311-321. SPRINGER Cardiovascular Drugs and Therapy |
| ISSN: | 0920-3206 |
| Popis: | Background The use of sodium–glucose co-transporter 2 inhibitors (SGLT2i) is currently expanding to cardiovascular risk reduction in non-diabetic subjects, but renal (side-)effects are less well studied in this setting. Methods Male non-diabetic Sprague Dawley rats underwent permanent coronary artery ligation to induce MI, or sham surgery. Rats received chow containing empagliflozin (EMPA) (30 mg/kg/day) or control chow. Renal function and electrolyte balance were measured in metabolic cages. Histological and molecular markers of kidney injury, parameters of phosphate homeostasis and bone resorption were also assessed. Results EMPA resulted in a twofold increase in diuresis, without evidence for plasma volume contraction or impediments in renal function in both sham and MI animals. EMPA increased plasma magnesium levels, while the levels of glucose and other major electrolytes were comparable among the groups. Urinary protein excretion was similar in all treatment groups and no histomorphological alterations were identified in the kidney. Accordingly, molecular markers for cellular injury, fibrosis, inflammation and oxidative stress in renal tissue were comparable between groups. EMPA resulted in a slight increase in circulating phosphate and PTH levels without activating FGF23–Klotho axis in the kidney and bone mineral resorption, measured with CTX-1, was not increased. Conclusions EMPA exerts profound diuretic effects without compromising renal structure and function or causing significant electrolyte imbalance in a non-diabetic setting. The slight increase in circulating phosphate and PTH after EMPA treatment was not associated with evidence for increased bone mineral resorption suggesting that EMPA does not affect bone health. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink